Chronic myeloid leukemia (CML) is a hematological malignancy characterized by the translocation between the chromosome 9 and 22, with the consequent generation of the BCR/ABL1 oncogene, responsible for increased proliferation, reduced apoptosis, and uncontrolled enter into the bloodstream of the immature myeloid cells (1). Here, ABL1 is linked to hematologic disorder.